EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States.
EYEG had news today so this helped the stock gain visibilty and momentum finance.yahoo.com RISK / REWARD swing idea and gap play Analysis: RSI is at 53 (not oversold) but is in the area of accumulation. MACD is moving in positive area Gap Zone hasn't been filled completely Daytrade idea: over .45 (confirm volume, RSI and Money Flow index) Swing Entry:...
Relative strength index (RSI-14) for Eyegate Pharmaceuticals, Inc. (EYEG) is at 35.36. Stock price escalated 6.42% to finalize at $0.58 throughout previous buying and selling session. EYEG is trading -79.65% downward from the 52-week high mark and 17.24% above from the fifty two-week low mark.